Close Menu

Meridian Bioscience

Life science product revenues nearly doubled, offsetting a continuing slide in the firm's diagnostics revenues.

According to some analysts, the selloff in IVD company shares may be an overreaction, and SARS-CoV-2-related testing will be needed for some time in the future. 

The firm has a molecular SARS-CoV-2 test in development on its Revogene platform and will be distributing an antigen test.

Of the 28 companies in the index, 12 firms saw their stock prices increase, while 16 firms' share prices decreased. 

While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.

The company said it broadened the scope of its life science products to include COVID-19 reagents used by manufacturers to develop rapid antigen tests.

Of the 28 companies in the index, 21 firms saw their stock prices increase throughout the first half of the year, while seven firms' share prices decreased.

Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased. 

Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.

Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.

Pages